|
 
- 现金
- 324 元
- 精华
- 0
- 帖子
- 145
- 注册时间
- 2013-9-17
- 最后登录
- 2021-1-4
|
新闻在arrowhead的公司网站上面可以看到：
http://arrowheadpharma.com/news-and-events/
Apr 13, 2016
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The
International Liver Congress™ 2016
点进去就可以看到pdf版本的新闻稿。
April 13, 2016
Arrowhead Pharmaceuticals Presents Promising ARC
-
520 Hepatitis B Data at The
International Liver Congress™ 2016
PASADENA, Calif.
--
(BUSINESS WIRE)
--
Arrowhead Pharmaceuticals, Inc.
(
NASDAQ
: ARWR) today announced that three
presentations are being made on ARC
-
520, its investigational medicine for the treatment of chronic hepatitis B infection, at
The International Liver Congress™ 2016 (ILC 2016), in
Barcelona, Spain
,
April 13
-
17, 2016
.
Collectively, these presentations demonstrate several important findings from Arrowhead's clinical and nonclinical studies of
ARC
-
520, including the following:
ARC
-
520 and entecavir produced rapid HBV DNA suppression with all hepatitis B e
-
antigen (HBeAg) positive,
treatment naïve patients achieving serum HBV DNA reductions of up to 5.5 log (99.9997%), and all HBeAg negative,
treatment naïve patients achieving reductions that put them below the limit of quantitation
ARC
-
520 effectively inhibited HBV cccDNA
-
derived mRNA with observed viral protein reduction in HBV patients of up
to 2.0 log (99%) after a single dose
Based on HBsAg epitope profile analysis, poster authors and Arrowhead collaborators had previously identified a
predictive hepatitis B surface
-
antigen (HBsAg) Clearance Profile associated with HBsAg clearance in antiviral therapy
cohorts
There was a significant association between the development of an HBsAg Clearance Profile and ARC
-
520 therapy in
HBV patients
Complexed HBsAg antibodies (anti
-
HBs) were developed and detected in HBV patients treated with ARC
-
520, which
may represent a recovery of the immune system response
After monthly administration of 6
-
11 doses of ARC
-
520 in chimpanzees chronically infected with HBV, the ARC
-
520
target site sequences remained virtually unchanged, indicating that no drug resistance developed during the
treatment period
Chris Anzalone
, Ph.D., president and CEO of
Arrowhead Pharmaceuticals
, said: "These are exciting results that
continue to show that ARC
-
520 can reduce the production of HBV viral proteins. We have ongoing multiple
-
dose and
combination studies designed to assess if this will allow the body's natural immune defenses to control the virus and lead to
a functional cure."
Copies of the poster presentations are currently available as ePosters to ILC 2016 attendees, and we have also made them
available on the Arrowhead website on the Events and Presentations page.
About ARC
-
520
Arrowhead's RNAi
-
based candidate ARC
-
520 is being investigated in the treatment of chronic HBV infection. The small
interfering RNAs (siRNAs) in ARC
-
520 intervene at the mRNA level, upstream of the reverse transcription process where
current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC
-
520 specifically to
determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s
-
antigen negative serum with or without seroconversion. Approximately 350
-
400 million people worldwide are chronically
infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers
globally. Arrowhead is currently conducting Phase 2b multiple dose and combination studies in chronic HBV patients. In
clinical studies to date, the most common reported adverse events in all subjects completing treatment were upper
respiratory infection and headache.
About
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
develops medicines that treat intractable diseases by silencing the genes that cause them.
Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA
interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a
specific protein. Arrowhead's RNAi
-
based therapeutics leverage this natural pathway of
gene silencing. The company's
pipeline includes ARC
-
520 and ARC
-
521 for chronic hepatitis B virus, ARC
-
AAT for liver disease associated with alpha
-
1
antitrypsin deficiency, ARC
-
F12 for hereditary angioedema and thromboembolic disorders, ARC
-
LPA for cardiovascular
disease, and ARC
-
HIF2 for renal cell carcinoma.
For more information please visit
www.arrowheadpharma.com
, or follow us on Twitter
@ArrowheadPharma
. To be added to
the Company's email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm
.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward
-
looking statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of
the date hereof. Our actual results may differ materially and adversely from those expressed in any forward
-
looking
statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success
of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10
-
K and subsequent Quarterly Reports on Form 10
-
Q discuss some of the important risk factors
that may affect our business, results of operations and financial condition. We assume no obligation to update or revise
forward
-
looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES
is a trademark of
Arrowhead Pharmaceuticals, Inc.
Source:
Arrowhead Pharmaceuticals, Inc.
View source version on
businesswire.com
:
http://www.businesswire.com/news/home/20160413005533/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone
, 626
-
304
-
3400
CFA
[email protected]
or
Investor Relations:
The Trout Group
Chad Rubin
, 646
-
378
-
2947
[email protected]
or
Media:
Russo Partners
Matt Middleman
, 212
-
845
-
4272
M.D.
[email protected]
Source:
Arrowhead Pharmaceuticals, Inc.
News Provided by Acquire Media
|
|
发表于 2016-4-18 02:38
